Business Context and Reporting Period
This Form 8-K Current Report was filed by Aileron Therapeutics, Inc. (noted as Rein Therapeutics, Inc. in metadata) on October 1, 2018. The report discloses the execution of a Severance Agreement with Donald V. Dougherty, the Company's Chief Financial Officer, as part of a program to provide uniform post-separation benefits to all officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change is the replacement of the employment agreement dated June 5, 2017, with a new Severance Agreement effective October 1, 2018. This agreement supersedes previous severance and post-employment payment terms for Mr. Dougherty.
Guidance, Outlook, and Management Commentary
The filing outlines specific severance conditions:
- Standard Termination: If terminated without Cause or for Good Reason (outside of a Change in Control), Mr. Dougherty is entitled to nine months of base salary and COBRA medical premiums.
- Change in Control: If termination occurs within 12 months of a Change in Control, benefits increase to twelve months of base salary, COBRA premiums, a lump sum equal to one times the target bonus, and full acceleration of unvested equity awards.
- Conditions: Receipt of benefits is conditioned upon the execution of a release of claims agreement.
The filing does not provide forward-looking guidance, risk factors, or commentary on unusual items beyond the executive departure context.
Investor Verification Checklist
- Verify the full text of the Severance Agreement in the upcoming Form 10-K for the year ending December 31, 2018.
- Confirm the total number of officers entering into similar severance agreements under the new program.
- Monitor for any subsequent announcements regarding Mr. Dougherty's actual departure or the triggering of Change in Control events.